- Reuters•8 months ago
Drug developer Allergy Therapeutics Plc said a study on suitable doses of its therapy to treat grass allergic rhinitis, or hay fever, did not find a recommended dose for a late-stage trial. This is the second allergy therapy in two weeks to run into trouble, after Circassia Pharmaceuticals Plc said last week that its cat allergy treatment failed in a late-stage trial.
We're sorry this is all we were able to find about this topic.
HHU.BE : Summary for ALLERGY THER. PLC LS-,001 - Yahoo Finance
ALLERGY THER. PLC LS-,001 (HHU.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
As of 8:08AM CET. Market open.
|Day's Range||0.29 - 0.29|
|52 Week Range||0.29 - 0.30|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|